Skip to main content
. 2024 Aug 8;10(5):e144. doi: 10.1192/bjo.2024.727

Fig. 2.

Fig. 2

(a) Risk estimates and 95% CI for diabetes risk by study month in individuals with bipolar I disorder treated continuously with aripiprazole (red) or olanzapine (blue). Vertical line ranges correspond to 95% pointwise CI. (b) Differences in (left panel) and ratios of (right panel) diabetes risk by study month among individuals with bipolar I disorder treated continuously with olanzapine compared with the risk of treatment with aripiprazole (reference group)